Side-effects of antiepileptic drugs: The economic burden  by de Kinderen, Reina J.A. et al.
Seizure 23 (2014) 184–190Side-effects of antiepileptic drugs: The economic burden
Reina J.A. de Kinderen a,b,*, Silvia M.A.A. Evers a, Roel Rinkens a, Debby Postulart b,
Christian I. Vader c, Marian H.J.M. Majoie b,d,e, Albert P. Aldenkamp b,d,f,g
aDepartment of Health Services Research, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands
bDepartment of Research and Development, Epilepsy Center Kempenhaeghe, Heeze, The Netherlands
cDepartment of Pharmacy, Epilepsy Center Kempenhaeghe, Heeze, The Netherlands
dMHENS School of Mental Health & Neuroscience, Maastricht University, Maastricht, The Netherlands
eDepartment of Neurology, Epilepsy Center Kempenhaeghe, Heeze, The Netherlands
fDepartment of Behavioral Sciences, Epilepsy Center Kempenhaeghe, Heeze, The Netherlands
gDepartment of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands
A R T I C L E I N F O
Article history:
Received 3 May 2013
Received in revised form 11 November 2013
Accepted 12 November 2013
Keywords:
Cost of illness
Medical expenditure
Adverse effects
Antiepileptic drugs
A B S T R A C T
Purpose: Antiepileptic drugs are a potentially effective treatment for epilepsy. Side-effects are, however,
common and the negative consequences necessitate treatment ranging from minor interventions to very
expensive hospitalization. This analysis has been conducted to provide insight into the costs of side-
effects due to antiepileptic drugs in The Netherlands from a societal perspective.
Method: Resources allocated to care (grouped according to health, patient and family and other) for ﬁve
different categories of side-effect were measured using a questionnaire. Standard cost prices were
derived from the Dutch costing manual. Chronic epilepsy patients were invited to complete the
questionnaire if they had experienced side-effects during the previous 12 months.
Results: Based on data from 203 patients, the total societal costs of common side-effects in 2012 are
estimated to be s20,751 CI:15,049–27,196 (US$26,675 CI:19,345–34,960) per patient per year. These
consist of: health care costs (mean s4458; US$5731), patient and family costs (i.e. informal care, mean
s10,526; US$13,531) and other costs (i.e. productivity losses, mean s5761; US$7406). Examining the
different categories of side-effects separately, ranging from the most to the least expensive category, the
cost estimates per patient per year were as follows: other (mean s13,228; US$17,005), behavioral (mean
s9689; US$12,455), general health (mean s7454; US$9582), cognitive (mean s7285; US$9365) and
cosmetic side-effects (mean s2845; US$3657). Subgroup analyses showed signiﬁcant differences in
costs between patients using monotherapy and those using polytherapy when looking at cognitive and
cosmetic side-effects.
Conclusion: These estimates should be considered in the overall assessment of the economic impact of a
pharmacotherapy.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Antiepileptic drugs (AEDs) are potentially an effective treat-
ment for patients with epilepsy. Treatment failure and poor
adherence are, however, very common in patients experiencing
side-effects due to AEDs. In approximately 25% of the patients,
side-effects lead to treatment discontinuation1–3 and have a
substantial, negative impact on the quality of life.3,4 Furthermore,
the negative consequences of side-effects can signiﬁcantly affect* Corresponding author at: Maastricht University, Department of Health Services
Research, Duboisdomein 30, 6200 MD Maastricht, The Netherlands.
Tel.: +31 43 38 81834; fax: +31 43 38 84162.
E-mail address: Reina.dekinderen@maastrichtuniversity.nl
(Reina J.A. de Kinderen).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.11.009the lives of relatives and friends of the patient, as well as society in
general.
Commonly occurring side-effects of AEDs are memory pro-
blems, fatigue, tremors, gastrointestinal symptoms, osteoporosis,
depression, drowsiness, dizziness, weight change, nausea, etc.5
These may require medical treatment ranging from a minor
intervention to very expensive specialist care and hospital
admission. In addition to these health care costs, patient and
family costs (i.e. informal care) and costs in other sectors (e.g. loss
of employment) can be substantial.
Numerous studies have calculated the economic burden of
epilepsy in many countries.6–12 Only one study assessed the direct
costs of severe idiosyncratic reactions due to antiepileptic drugs in
hospitalized patients from an institutional perspective.13 None
focused on the economic burden of the commonly occurring side-
effects due to AEDs in their analyses. In order to accurately reﬂectvier Ltd. All rights reserved.
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side-effects should be included in the analysis.
The overall objective of this study is, therefore, to estimate the
annual health care costs, the patient and family costs and costs in
other sectors of commonly occurring side-effects due to AEDs in
The Netherlands.
2. Methods
All epilepsy patients using antiepileptic drugs, who visited the
tertiary epilepsy center Kempenhaeghe, Heeze, The Netherlands,
between September 2011 and November 2011, received a patient
information letter by mail including an invitation to complete a
questionnaire (N = 1386). The letter contained information about
the content of the questionnaire and the purpose of the study.
Furthermore, the letter stated that participation was completely
voluntarily and that participant’s data would be anonymously
analyzed and reported. Participants were invited to complete the
questionnaire only when they had experienced side-effects during
the previous 12 months. For young children and patients with
severe mental retardation, proxy measures were taken. The
questionnaire could either be completed digitally via the internet
or on paper. All participants (patients, parents or caregivers) gave
their informed consent.
2.1. Questionnaire
The Side-effects of AED treatment (SIDAED)14 was used as the
basis for the questionnaire. The ten original side-effect categories
of the SIDAED were compressed into four categories, in order to
focus on the most common side-effects and to condense the
questionnaire. The categories used in this study were: cognition
(e.g. memory problems, slowing of thought process, feeling drowsy
or sleepy, etc.), cosmetic (e.g. weight problems, skin rash, surplus
saliva, etc.), behavioral (e.g. depressed, irritated, pressurized or
excitable, etc.) and general health (e.g. general CNS, vision,
headache, gastrointestinal, sexuality/menses complaints). A ﬁfth
category was added (‘other’ complaints) to allow patients to report
side-effects that they could not classify within one of the
aforementioned categories.
The questionnaire starts with some basic demographic ques-
tions (age, sex, education, employment, and AED usage). Then the
opening question of the ﬁrst subdivision of the questionnaire is:
‘Have you experienced any cognitive side-effects, such as slow
reaction or memory and concentration problems, during the last
12 months?’ If not, the questions about cognitive side-effects can
be skipped and the patient can go on to the subdivision of the
questionnaire dealing with cosmetic side-effects and answer
whether or not they have encountered, for example, skin rash,
hair loss or weight gain, during the last 12 months, etc. If a patient
has experienced cognitive side-effects, he or she is asked to
describe their symptoms and to respond to all the questions about
use of resources belonging to this speciﬁc category. All categories
of the questionnaire are dealt with in this way. The questions about
resource use are exactly the same for all ﬁve categories. As the cost
analysis is performed from a societal perspective, the measure-
ment of resources has to be broad, i.e. it must encompass all related
costs, irrespective of who pays. Use of resources in the categories
health care, patient and family and other sectors are, therefore,
measured. Health care usage includes visits to the general
practitioner, specialists, psychologists, alternative health care
practitioners, paramedics (i.e. dietician, speech therapist, physio-
therapist), admission to a general, academic or psychiatric hospital
or to an epilepsy center, care received, including day care,
occupational care, social services, home care, prescribed and
over-the-counter (OTC) medication for side-effects. Patient andfamily resource use includes informal care and out of pocket
expenses. The sector ‘other resource use’ includes loss of
productivity and absenteeism from activities of daily life.
2.2. Analyzing costs
The total costs were estimated using a bottom-up approach,
where information on each element of service used was multiplied
by an appropriate standardized unit cost and summed to provide
an overall total cost.15 The index year for the study was 2012
(consumer price index (inﬂation) number: 111.39; exchange rate
1.00 EUR = 1.2855 USD)16 and standard cost prices were derived
from the Dutch Manual for Costing17 or (if not available) calculated
mean cost prices according to providers were used. In accordance
with these guidelines, medication costs were calculated based on
daily deﬁned dosage taken from the Dutch pharmaceutical
therapeutic compass combined with the Dutch consumer reim-
bursement price of medication.18 When data on medication was
diverse, lowest cost prices for the speciﬁc medication were used.
Costs of informal care and absenteeism from daily activity were
calculated using standardized cost prices based on shadow prices.
‘Shadow pricing’ is a method used to impute values on cost items
for which no market prices are available. In this case, the minimum
wage rate of The Netherlands was used to estimate the cost of
informal care provided by relatives or friends of the patient and
losses of daily activity. For out-of-pocket payments, costs declared
by the patient were used.
Productivity losses from paid work were quantiﬁed in terms of
net cumulative number of days of sick leave over a period of 12
months. In the case of partial sick leave, we assumed that subjects
were 100% productive during the hours of partial work resump-
tion. Productivity losses were calculated based on the Human
Capital Approach (HCA). The cumulative number of calendar days
of sick leave was converted into work-hour equivalents based on
the mean number of work-hours per week registered by the
patients. The costs of production losses were calculated by
multiplying the number of sick leave hours by the estimated
reference cost of production loss for an employee per hour of sick
leave.17
Despite the usual skewness in the distribution of costs,
arithmetic means are generally considered to be the most
appropriate measures for describing cost data.19,20 Therefore,
arithmetic means are presented. However, to check for sample
uncertainty, non-parametric bootstrapping was used. This method
is based on random sampling, with replacement based on the
participant’s individual data.21 Non-parametric bootstrapping
avoids the need to make assumptions about the shape of the
distribution, such as normality, and instead uses the observed
distributions of the cost data in the study being analyzed. In this
study, the non-parametric bootstrap resample method was applied
with 1000 replications. The bootstrap replications were used to
calculate 95% conﬁdence intervals around the costs, based on the
2.5th and 97.5th percentiles. The data on costs were analyzed using
the statistical package IBM SPSS 20.0 (SPSS, IBM Corporation,
Chicago, USA) and MS-Excel 2010 (Excel, Microsoft Corporation,
Washington, USA).
2.3. Subgroup and sensitivity analyses
Subgroup analyses were performed to check for differences
between groups. Firstly, a combination of AEDs can produce
negative interactions which can lead to side-effects. There is,
however, evidence that AED toxicity may show a greater
correlation with total drug load than with the number of AEDs
administered.22 Drug loads for each individual patient were
estimated as the sum of the prescribed daily dose (PDD)/deﬁned
Table 1
Demographic characteristics (N = 203).
N %
Age mean (range) 38 (2–81)
0–19 years of age 52 25.6
20–39 years of age 49 24.1
40–59 years of age 66 32.5
60 years of age or older 36 17.7
Female 102 50.2
Education
No education 20 9.9
Too young for school 13 6.4
At primary school 1 0.5
Special education 17 8.4
Primary education 18 8.9
Lower level secondary education 31 15.3
Higher level secondary education 11 5.4
Secondary vocational education 52 25.6
Higher education 40 19.7
Paid work 56 27.6
Number of different AEDs per patient
One 59 29.1
Two 66 32.5
Three 47 23.2
Four 21 10.3
Five 6 3.0
Six 3 1.5
Seven 0 0
Eight 1 0.5
R.J.A. de Kinderen et al. / Seizure 23 (2014) 184–190186daily dose (DDD) ratios for each AED included in the treatment
regimen,22 where DDD corresponds to the assumed average
maintenance daily dose of a drug prescribed for its main indication.
Two separate subgroup analyses were, therefore, performed to
check for differences between patients on monotherapy or
polytherapy and on the total drug load. Secondly, as side-effects
of AEDs may differ over time, another subgroup analysis was
performed to check for differences between children and adults.
In addition, a sensitivity analysis was performed to assess
uncertainty. As different methods can be used to put a value on
productivity losses, we corrected for the methodological uncer-
tainty by calculating productivity losses on the basis of the friction
cost method (FCM) instead of the HCA. The FCM is based on the
assumption that an organization needs a certain time span to
replace the absent worker. The deﬁnitive number of days absent
from work is limited to the duration of the friction period,
determined in The Netherlands to be 23 weeks.17
3. Results
In total, 210 patients from the tertiary epilepsy center
completed the questionnaire. Although we asked patients only
to ﬁll out the questionnaire if they had experienced any side-effect
during the previous 12 months, seven questionnaires were
returned which described neither side-effects nor costs and so
they were excluded from the analysis. The characteristics of all
included participants are shown in Table 1.
All patients included in the analysis had experienced one or
more side-effects due to AEDs during the previous 12 months, in
most cases (85%) related to general health. Cognitive side-effects
are the second most commonly reported problem amongTable 2
Unit prices and annual mean costs per patient.
Unit price (s) Per side-effect category
Cognitive
N = 157
Cosm
N = 85
Health care costs
GP visits 29.56a 22.78 23
Specialist visits 76.02a 189.81 89
Blood sample 23.50a 20.66 13
Paramedic visits 32.73a 62.75 14
Psychologist visits 81.30a 84.41 8
Alternative care 53.85b 41.16 3
General hospital 459.29a 196.00 59
Academic hospital 607.1a 3.87 7
Epilepsy center 459.29a 175.52 32
Psychiatric care 244.95a 3.12 0
Day care (half day) 125.64a 13.60 67
Home care 36.95a 522.24 0
Social services 59.59a 72.49 1
Occupational health services 55.00b 25.57 12
Prescribed medication Variablec 1.51 80
OTC medication Variablec 1.61 15
Total health care costs 1437.11 429
Patient and family costs
Informal care 13.20a 4111.31 1815
Out of pocket Variabled 6.22 0
Total patient and family costs 4117.53 1815
Other costs
Production losses 31.72a 748.90 274
Daily routine losses 13.2a 952.84 319
Total other costs 1701.73 594
Total costs 7256.38 2838
Note: GP: general practitioner, OTC: over-the-counter. Costs are expressed in Euros, in
a Dutch guidelines for costing studies.
b Respective providers or professional organizations.
c Dutch pharmaceutical therapeutic compass.
d Costs mentioned by participants.
e Mean annual costs due to side-effects per patient. Total N = 203 represents the num
numbers mentioned per side-effect category do not add up to 203.participants (77%), followed by the categories behavioral (68%),
cosmetic (42%) and other (7%).
Table 2 lists the reference prices per unit and the arithmetic
mean total costs per category. Table 3 shows the bootstrapped Totale
etic Behavior
N = 139
General health
N = 172
Other
N = 15
N = 203
.65 21.48 35.40 165.54 84.46
.44 182.12 224.08 391.40 527.73
.27 15.38 28.01 86.17 62.17
.25 30.85 65.27 21.82 132.53
.61 159.09 36.40 319.78 232.29
.17 42.23 39.14 0.00 95.23
.44 0.00 216.29 0.00 359.74
.14 0.00 225.90 0.00 197.38
.42 489.03 376.51 183.72 816.77
.00 1.76 0.00 0.00 3.62
.99 20.79 167.28 16.75 196.20
.00 826.46 642.54 256.19 1533.15
.40 60.45 9.35 11.92 106.85
.29 20.97 26.54 47.67 65.30
.48 10.25 3.16 466.93 79.06
.82 1.92 16.25 3.33 23.20
.37 1882.78 2112.11 1971.21 4475.27
.00 5002.70 2840.70 8770.08 10,420.08
.00 1.44 4.12 32.00 11.66
.00 5004.14 2844.82 8802.08 10,472.14
.66 1386.89 967.67 118.42 2472.49
.91 1347.43 1536.09 2424.69 3274.18
.57 2734.32 2503.76 2543.11 5746.67
.94 9621.23 7460.70 13,316.40 20,694.09
dex year 2012. Exchange rate 1 EUR = 1.2855 USD.
ber of patients. As patients may have experienced more than one side-effect, the
Table 3
Bootstrapped annual mean costs per patient (conﬁdence interval) base case and sensitivity analyses.
Per side-effect category Totala
Cognitive
N=157
Cosmetic
N=85
Behavior
N=139
General health
N=172
Other
N=15
N=203
Health care costs
GP visits 23.02 (13–36) 23.41 (13–35) 21.40 (12–32) 34.20 (23–51) 160.13 (45–369) 84.22 (57–117)
Specialist visits 189.67 (136–251) 90.07 (52–134) 181.29 (138–232) 223.50 (164–299) 392.15 (249–569) 527.25 (420–648)
Blood sample 20.67 (13–31) 13.19 (7–20) 15.46 (9–23) 27.90(21–36) 85.27 (24–174) 62.31 (46–82)
Paramedic visits 63.34 (19–129) 14.07 (4–27) 30.32 (7–61) 64.36 (21–123) 21.43(0–65) 132.71 (69–211)
Psychologist visits 84.11 (51–121) 8.58 (1–19) 158.77 (77–261) 35.80 (18–59) 313.79 (0–905) 229.82 (139–334)
Alternative care 40.41 (12–79) 3.12 (0–9) 42.10 (11–91) 39.71 (9–81) 0.00 96.22 (29–197)
General hospital 189.20 (34–423) 59.25 (5–139) 0.00 215.75 (83–377) 0.00 357.45 (118–688)
Academic hospital 3.80 (0–12) 7.12 (0–21) 0.00 230.80 (4–565) 0.00 193.53 (9–490)
Epilepsy center 174.03 (57–342) 32.17 (0–80) 499.25 (149–899) 373.36 (128–697) 187.57 (31–398) 811.08 (391–1349)
Psychiatric care 3.16 (0–10) 0.00 1.72 (0–5) 0.00 0.00 3.64 (0–10)
Daycare (half day) 13.70 (7–22) 65.62 (3–184) 21.19 (5–49) 165.45 (3–476) 17.27 (0–50) 200.07 (31–489)
Home care 522.47 (50–1295) 0.00 837.50 (180–1933) 653.89 (39–1917) 266.95 (0–1025) 1562.01 (564–2863)
Social services 70.97 (17–142) 1.44 (0–4) 60.20 (26–99) 9.35 (2–20) 11.63 (0–36) 114.86 (52–197)
Occupational health services 25.92 (12–42) 12.07 (1–30) 20.60 (6–38) 26.38 (13–42) 48.22 (0–139) 65.62 (30–113)
Prescribed medication 1.50 (0.1–3) 82.16 (10–209) 10.29 (2–23) 3.15 (0–7) 471.45 (18–1285) 80.56 (22–166)
OTC medication 1.62 (0–4) 15.66 (5–30) 1.82 (0–5) 16.55 (8–26) 3.33 (0–10) 23.31 (13–34)
Total health care costs 1421.15 (790–2213) 432.49 (256–649) 1887.24 (1061–2955) 2119.69 (1153–3321) 1980.87 (721–3576) 4458.30 (3051–6034)
Patient and family costs
Informal care 4113.53 (2695–5740) 1830.70 (205–4190) 5031.12 (2887–7604) 2841.91 (1494–4558) 8690.13 (945–19,786) 10,440.68 (6364–15,217)
Out of pocket 6.11 (0–13) 0.00 1.53 (0–4) 4.11 (1–8) 31.20 (0–96) 11.75 (3–23)
Total patient and family costs 4111.98 (2473–6082) 1820.71 (166–3985) 5029.84 (2877–7539) 2803.82 (1525–4449) 8782.78 (945–19,577) 10,526.12 (6348–15,549)
Other costs
Production losses 760.16 (158–1564) 274.40 (0–702) 1351.80 (392–2585) 977.92 (260–1817) 118.66 (0–355) 2460.95 (732–4447)
Daily routine losses 968.95 (496–1535) 321.08 (4–829) 1340.97 (683–2099) 1535.99 (947–2232) 2404.40 (542–4961) 3311.08 (2050–4680)
Total other costs 1703.01 (805–2712) 598.63 (90–1284) 2758.02 (1532–4124) 2496.19 (1589–3638) 2575.75 (672–5277) 5761.00 (3719–8324)
Total costs 7284.59 (5109–9844) 2845.24 (1120–5295) 9689.01 (7030–12,770) 7454.17 (5265–9890) 13,228.42 (3850–25,071) 20,751.20 (15,049–27,196)
Sensitivity analyses
Monotherapy total costs 2678.75 (1551–3925) 1002.11 (511–1878) 7154.23 (3419–12,337) 6134.73 (2846–9937) N.a. 12,951.49 (6624–23,228)
Polytherapy total costs 9012.12 (5993–12,290) 3388.79 (1014–6489) 10,497.58 (6876–14,534) 8028.52 (5309–11,168) N.a. 24,515.68 (17,291–33,676)
Difference polytherapy vs. monotherapy 6333* (3111–9844) 2268* (245–5327) 3413 (2495 to 8471) 1894 (2531 to 6255) N.a. 11,564 (1069 to 22,324)
Age 1–18 total costs 9164.14 (4388–14,698) 992.74 (269–1962) 10,689.29 (5114–17,768) 6844.33 (2467–12,230) N.a. 24,368.92 (12,120–40,332)
Age>18 total costs 6785.27 (4342–9682) 3372.30 (1005–6273) 9257.84 (6294–13,072) 7716.22 (5236–10,501) N.a. 19,482.15 (13,391–26,078)
Difference age>18 vs. age 1–18 2379 (8425 to 3453) 2380 (151 to 5336) 1431 (9459 to 5453) 872 (5387 to 6162) N.a. 4887 (22,124 to 9615)
FCM production losses 575.89 (73–1194) 273.73 (0–655) 1063.47 (366–1919) 617.68 (198–1163) 118.66 (0–355) 1917.58 (765–3379)
FCM total costs 7104.20 (4882–9705) 2844.16 (1064–5090) 9266.24 (6543–12,186) 7206.38 (5205–9495) 13,223.24 (10,041–16,631) 20,070.83 (14,750–26,571)
Note: CI: conﬁdence intervals based on the 2.5th percentile and the 97.5th percentile, GP: general practitioner, OTC: over-the-counter, Na: not applicable, FCM: friction cost method. Costs are expressed in Euros, index year 2012.
Exchange rate 1 EUR=1.2855 USD.
a Mean annual costs due to side-effects per patient. Total N=203 represents the number of patients. As patients may have experienced more than one side-effect, the numbers mentioned per side-effect category do not add up to
203.
* Signiﬁcant.
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Table 4
Number of AEDs, mean drug load and bootstrapped annual mean costs per patient (N = 162).
Number of AED Drug load SD Totala CI
One 0.74 0.51 10,499.58 6176–15,772
Two 1.39 1.0 16,953.17 9772–29,208
Three 2.37 1.27 26,883.80 12,065–47,156
Four or more 3.68 2.1 30,215.72 10,142–57,502
Note: AED: antiepileptic drug, SD: standard deviation, CI: conﬁdence intervals based on the 2.5th percentile and the 97.5th percentile, N = 162: represents the number of
patients aged 16 years or over. Costs are expressed in Euros, index year 2012. Exchange rate 1 EUR = 1.2855 USD.
a Bootstrapped mean annual costs due to side-effects per patient.
R.J.A. de Kinderen et al. / Seizure 23 (2014) 184–190188mean total costs of all categories and their 95% conﬁdence
intervals. The arithmetic mean costs are comparable to the
bootstrapped mean costs. On the whole, most costs are generated
in the patient and family sector compared to costs in health care
and other sectors. Overall, informal care is the main cost driver
accounting for 51% of the total annual costs per patient. Production
losses account for 43% of the other sector costs, but only for 12% of
the overall total costs. However, only 28% of the patients had a paid
job and were, therefore, responsible for the costs of production
losses. Patients without a paid job generated the costs of daily
routine losses.
Table 3 shows the differences in costs between the side-effect
categories. As can be seen, admissions to a general or academic
hospital are frequently categorized under general health side-
effects, while behavioral problems lead to numerous admissions to
the epilepsy center. Resource use related to daycare occurs most
often in the general health category; homecare is an expensive factor
in the cognitive, behavioral and general health side-effects
categories. Prescribed medication only leads to high costs in the
category ‘other’. This is in fact due to one individual who underwent
treatment with Teriparatide injections for osteoporosis during the
previous 12 months (total costs > 5000 Euros, US$6428).18
Overall, total costs per patient in the category ‘other side-
effects’ are the highest. These are based on a small group (n = 15) of
patients of whom a few experienced side-effects due to AEDs
which speciﬁcally led to high costs of informal care and many
losses in daily routine.
3.1. Subgroup and sensitivity analyses
Table 3 shows the bootstrapped means of the subgroup
analyses. Firstly, mean costs are calculated separately for patients
on monotherapy and those on polytherapy. Of the 203 participants,
61 were on monotherapy. Overall, mean costs due to side-effects
per patient are considerably higher in the polytherapy group. For
the categories cognitive and cosmetic side-effects, the mean costs
for a polytherapy patient is three times more than for a patient on
monotherapy (s2679 (US$3444) vs. s9012 (US$11,585) resp.
s1002 (US$1288) vs. s3389 (US$4357)). The difference between
mean costs for monotherapy and polytherapy in the categories
behavioral side-effects and general health side-effects are less
prominent and statistically not signiﬁcant (s7154 (US$9196) vs.
s10,498 (US$13,495) and s6135 (US$7887) vs. s8029
(US$10,321)). As there are only two patients on monotherapy
who have experienced any other side-effects, bootstrapping is
impossible and presenting the arithmetic mean would be
incorrect.
Table 4 shows the bootstrapped means of the subgroup analysis
performed when taking the total drug load into account. We
applied the average adult DDD, used for the main indication as
reﬂected by the ATC code to calculate total drug load.23 For
medicinal products approved for use in children, dose recommen-
dations will differ according to age and body weight. We, therefore,
included only patients aged 16 years and over in this subgroup
analysis. AED loads increased with increasing number of AEDs inthe treatment regimen, from 0.7  0.5 for patients on monotherapy
to 1.4  1, 2.4  1.3 and 3.7  2.1 for those on two, three and 4
AEDs, respectively. Moreover, total costs of side-effects also increase
when drug loads rise.
Secondly, total mean costs were calculated separately for
children and adolescent patients (aged 1–18) and for adult patients
over 18 years of age. Of the 203 participants, 50 patients were aged
between 1 and 18 years. Overall, total mean costs per patient due
to side-effects seem to be higher in children and adolescents.
However, in the categories cosmetic and general health, side-effect
costs were higher in the adult group. No statistically signiﬁcant
differences in costs were found in the different side-effect
categories. Again, showing the bootstrapped or the arithmetic
mean of this subgroup analysis in the other side-effects category
would be incorrect as the group is small (4 children vs. 11 adults).
Furthermore, Table 3 shows the result of the bootstrapped
means of the sensitivity analysis. When using the FCM instead of
the HCA to calculate productivity losses in a sensitivity analysis,
total costs of all side-effects decreased to s20,071 (US$25,801).
The FCM was applied in four patients in whom the maximum
length of the friction period (23 weeks) was exceeded. More
speciﬁcally, costs of cognitive side-effects decreased from s7285
(US$9365) to s7104 (US$9132), of behavioral side-effects from
s9689 (US$12,455) to s9266 (US$11,911) and of general side-
effects from s7454 (US$9582) to s7206 (US$9263). As the
patients who exceeded the maximum length of the friction period
did not report any cosmetic or other side-effects, these costs
remained the same.
4. Discussion
Based on reports on use of resources (in the categories health
care, patient and family, and other) by 203 epilepsy patients with
side-effects, the general societal costs of common side-effects in
2012 due to antiepileptic drugs is estimated to be s20,751
(US$26,675) per patient. Patient and family costs were on the
whole higher than the cost of health care or the costs in the ‘other’
sector. Examining the different categories of common side-effects
separately, other side-effects generated the most (s13,228;
US$17,005) and cosmetic side-effects the least costs (s2845;
US$3657) per patient per year. Behavioral effects generated the
second highest costs per patient per year (s9689; US$12,455)
closely followed by costs of general health side-effects (s7454;
US$9582) and cognitive side-effects (s7285; US$9365). Further-
more, several subgroup analyses only showed signiﬁcant differ-
ences in costs between patients on monotherapy and those on
polytherapy within the cognitive and the cosmetic side-effects
categories.
Although many articles dealing with ‘cost of epilepsy’ have been
published in the literature, we did not ﬁnd any studies focusing on
the cost of common side-effects due to AEDs. It can be stated that
the economic burden of common side-effects is considerable
compared with the costs of the disease itself. For example,
estimates show total costs of epilepsy per patient per year ranging
between s625 and s4292 (US$803–5517) in The Netherlands,24
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Denmark,26 and s7738 (US$9947) in Germany.27 Although these
cost of illness studies used different methods, databases and study
periods, they included roughly the same cost categories (e.g. direct
and indirect) as those used in this article. For example, Pugliatti
et al.28 estimated the cost of epilepsy in Europe based on a review
with economic modeling and also concluded that costs outside the
formal health care sector were the single most costly resource
item, productivity losses being the most dominant cost category. In
his review of twelve cost of epilepsy studies, Strzelczyk et al.29
found that indirect costs comprised between 12% and 85% of the
total costs. These results are, however, highly dependent on the
method used to measure this cost category. Moreover, the lack of
standardization of productivity cost methodology is a serious
concern. Applying different methods can lead to (large) variations
in productivity cost estimates, and so the trustworthiness of
outcomes may become a matter of debate. Furthermore, patients
are treated differently depending on whether they are employed
on a full-time or part-time basis or have no work at all. E.g. consider
a patient who has severe seizures or side-effects which do not
allow him/her to take a job. No productivity losses due to side-
effects are calculated for this patient as he/she has no paid work.
Whereas an epilepsy patient with better controlled epilepsy and/or
side-effects can create high loss of productivity costs whenever he/
she is not able to work due to seizures or side-effects. As a result
the calculated costs might lead to incorrect conclusions. However,
as we chose to follow existing Dutch guidelines for costing, we
tried to reduce the problems of productivity loss calculations to a
minimum. Additional methodological differences between our
study and other cost of illness studies, concern the sources of
information and cost components included. To be more speciﬁc, in
contrast to most other cost of illness studies, we included informal
care costs, the component which proved to be the most dominant
direct cost category outside the health care sector in our study. The
euro value of the burden associated with informal care may have
been even higher than estimated, as we assumed a minimum wage
for all informal care providers.
Our results conﬁrm that from an economic perspective, it is
very important that the treatment of epilepsy patients is primarily
concerned with balancing seizure control and adverse effects. Side-
effects exert a high burden, not only for society, but also for the
individual patient. One study showed that patients are willing to
pay s879 (US$1130; £709, £1 = s1.24, 2012 exchange rate) per
month to achieve 100% seizure reduction with no adverse effects,
but only s216 (US$278; £174) per month for a drug that provided
seizure freedom but also caused hair loss.30
As mentioned earlier, we found a signiﬁcant difference in costs
between patients on monotherapy and polytherapy. Early studies
emphasized that polytherapy is usually detrimental, since it is
associated with a considerable burden due to side-effects, with
only modest advantages in terms of seizure control.31 However,
there is also evidence that AED toxicity may be related to total drug
load rather than to the number of AEDs administered.22 Canevini
et al.32 provided evidence that adverse events did not differ
between monotherapy and polytherapy patients, and did not
correlate with AED load. Although our primary aim was not to
contribute to this debate, our data show that drug load increased
with an increase in the number of AEDs included in a polytherapy
regimen. Furthermore, costs due to side-effects increased with
increase in drug load and number of AEDs administered.
Relevant within the scope of this paper, but not touched upon
due to the lack of data, is the high cost related to (pharmacological)
treatment of and productivity losses due to chronic side-effects of
long-term AED treatment. For instance, in patients undergoing
AED treatment which carries a high risk of osteoporosis (e.g.
enzyme inducing drugs), side-effect costs will increase as thosepatients eventually have to use additional (pharmacological)
treatments in order to overcome these chronic side-effects or
bring them to a halt. Another example which might induce long-
term costs is the patient with cognitive impairments due to long-
term AED treatment who becomes unable to hold down a job.
Research using longitudinal data is needed to further explore the
costs and inﬂuences of chronic side-effects due to long-term AED
treatment.
Our study does have certain limitations. Firstly, only subjective
symptoms and related health care use of resources reported by
patients were used. It has been proven that the frequency at which
side-effects of antiepileptic drugs are reported in a given
population is dependent on the method of assessment. Reliance
on unstructured interviews or spontaneous reporting under-
estimates the burden of toxic effects of antiepileptic drugs,
whereas use of screening measures, such as questionnaires or
checklists, can result in overestimation.33 Furthermore, caution
should be exercised when relying on patient-recorded cost data34;
recall bias is to be expected especially considering the chosen time
scale (12 months). Using a cost questionnaire, however, enabled us
to obtain actual data on patient and family costs, including
informal care, which cannot be captured through other sources
such as hospital databases and patient records.
Secondly, since we did not include a control group in our
analyses, we were not able to compare health care costs in people
with epilepsy with the health care costs of those without epilepsy.
It has, however, already been proven that patients suffering from
epilepsy are associated with higher expenditure, both because of
being more likely to have expenses and because the average
expense is higher. In a comparison of health care expenditure of
people with epilepsy and non-epileptics, Yoon et al.35 found that
the average excessive direct health care expenditure due to
epilepsy was s3518 (US$4523). Furthermore, they found that
adults with epilepsy received signiﬁcantly more informal care than
people without epilepsy. Jennum et al.26 showed that the direct net
annual health care and indirect costs were s14,575 (US$18,736)
for patients and s1163 (US$1495) for controls, i.e. a consequent
excess cost of s13,412 (US$17,241).
Thirdly, our study has a potential bias toward severely affected
patients at an epilepsy center as only 30% of the patients were on
monotherapy. Moreover, we had a participation rate of only 15%
which can lead to possible selection bias. This low response rate is
mainly due to a combination of factors: patients without any side-
effects and/or patients unwilling to participate in the study.
Furthermore, only 18% of the participants was 60 years or older
which may mean the costs are underestimated as chronic side-
effects due to long-term AED usage (e.g. osteoporosis) can result in
high costs.
In conclusion, this study, despite its limitations, demonstrates
the economic burden induced by patients with antiepileptic side-
effects as viewed from societal perspective in The Netherlands.
Assuming that in The Netherlands, more than 80,000 people have
epilepsy,36 that about 88% of the patients experience side-effects37
and that the demonstrated costs can be as high as s20,751
(US$26,675) per patient per year, side-effects due to antiepileptic
drugs will have a major impact on health care costs. These ﬁgures
should be considered along with the costs associated with drug
acquisition, delivery and treatment of all clinical successes and
failures, in the overall assessment of the economic impact of
pharmacotherapy.
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